ment therapy [1] [2] [3] . The majority of these patients Background. Chronic hepatitis C virus (HCV ) infec-acquire HCV through transfusion of unscreened blood tion is prevalent among patients on renal replacement products, while the renal allograft and nosocomial therapy. Viral genomic differences can contribute to transmission during haemodialysis represent other diversities in clinical manifestation. The distribution of modes of infection [4] [5] [6] [7] . Once infected, spontaneous HCV genotypes depends on the geographical region clearance of HCV is rare. The clinical consequences of and risk factors unique to the patient population. We chronic HCV infection in these patients are variable, determined the HCV genotypes in patients on renal ranging from a carrier state with minimal hepatic replacement therapy in order to define the genotypic pathology to rapidly progressive chronic active hepatprofile and examine the relationship between genotype, itis and cirrhosis [8] [9] [10]. There is accumulating evidmode of renal replacement therapy, and the prevalence ence that viral factors may play a role in the as well as severity of liver disease.
Introduction
Patients and controls The hepatitis C virus (HCV ) is a major cause of chronic liver disease among patients on renal replace-T. M. Chan et al. 732 infection by testing for anti-HCV; 50 (5.8%) patients who Histological assessment were seropositive for HCV RNA by the nested polymerase chain reaction (PCR) assay were included for genotype Histological assessment of percutaneous liver biopsy was studies. Genotyping was also performed for 26 patients with done by the same pathologist (PCW ) without knowledge of post-transfusional chronic hepatitis C, without renal disease. the patients' clinical data. Liver pathology was scored accordNone of the subjects was sero-positive for HBsAg, or had ing to 'inflammatory activity', 'architectural abnormality', isolated anti-HBc. and the degree of 'bile duct damage', adding up to a 'total histological score' [9] .
Virological and biochemical assays Statistics
Anti-HCV was assayed every 6 months by a secondResults were expressed as mean±SD. The median values generation enzyme immunoassay (EIA II, Abbott were also given for some variables. Comparisons were made Laboratories, Chicago, IL), which detected antibodies to using the Mann-Whitney test, the Kruskal-Wallis test, the c100-3, c-33, and c-22 antigens. HCV RNA was assayed Chi-square test, and the Fisher's exact test where appropriate. every 6 months in all anti-HCV-positive subjects, and in Two-tailed P values of <0.05 were considered statistically anti-HCV-negative subjects with non-A non-B hepatitis, by significant. nested PCR as described previously [5] . Serum level of liver enzymes were monitored at least every 6 weeks. Chronic hepatitis was denoted by transaminase levels of more than Results twice the normal upper limit for more than 6 months.
HCV RNA was detected in serum samples from Determination of HCV genotypes 50(5.8%) of 860 patients on renal replacement therapy. The group comprised 21 renal allograft recipients, 25 HCV genotypes were determined from a cross-sectional patients on haemodialysis, and four patients on periblood sample by restriction fragment length polymorphism toneal dialysis, giving seroprevalence rates of 6.4, 19.2, (RFLP) analyses of the 5∞-untranslated genomic region and 1% respectively. Among the 21 renal allograft (5∞UTR) [16 ] . Briefly, the 5'UTR was reverse transcribed recipients, 14 had the transplant operation performed and amplified by PCR, using the outer primers in Hong Kong, while the remaining seven had received 5∞-TCATGGTGCAACGGTCTACGAGACCT-3∞
(antisense), 5∞-CTGTGAGGAACTACTGTCTT-3∞ (sense), and renal allografts in China. The age of renal allograft the inner primers 5∞-CACTCGCAAGCACCCTATCAGG-recipients, dialysis patients, and post-transfusional con-
5∞-TTCACGCAGAAAGCGTC-trols (40.3±15.5) were similar ( Table 1) . Renal allo-TAG-3∞ (sense). The amplicons were digested by two restric-graft recipients had shorter duration of dialysis before tion enzymes HaeIII/Rsal and Mval/Hinfl for differentiation transplantation (32±34 months vs 121±63 months, into genotypes 1-6, according to the Simmonds nomenclature P<0.0001) and had received fewer blood transfusions [11] . Subtypes 1a/c and 1b were further differentiated by than patients on dialysis (P<0.05). The prevalence of digestion with the restriction enzyme BstUI. Subtypes 2a/c chronic hepatitis was similar between renal allograft and 2b, as well as subtypes 3a and 3b were further differenrecipients and patients on dialysis. Twenty-eight tiated by digestion with the restriction enzyme ScrFI.
patients (14 renal allograft recipients and 14 dialysis
Differentiation between genotypes 1 and 6 was confirmed by sequencing of the 5∞UTR. patients) consented to liver biopsy, which showed 'minimal change' in five renal allograft recipients and chronic hepatitis C in this locality. The predominance of genotype 1b is similar to data obtained from haemoseven dialysis patients, and chronic active hepatitis in the remaining 16 patients. Renal allograft recipients dialysis patients in Korea [15] . Geographical variation in genotypic distribution within Asia, as illustrated by demonstrated higher 'total histological' and 'inflammatory activity' scores than patients on dialysis the predominance of type 1b in Hong Kong, Japan, Taiwan, and Korea, and 3a in Thailand, may be (P<0.05).
Genotype 1b, which was detected in 78% of patients attributable in part to the population migration to southeastern Asian countries in history [14, 17] . In (71 and 83% among post-transplant and dialysis patients respectively, P=NS), was the most prevalent contrast to reports from France and Belgium, we have not observed any change in genotype distribution with genotype, followed by 1a (10%) and 6a (8%)( Table 2 ). The prevalence of genotype 1b was similar between time of starting dialysis [18, 19] .
Differences in HCV genotype distribution between patients with renal failure and post-transfusional controls. The relative distribution of HCV genotypes did patients with or without renal failure in the same locality may suggest nosocomial transmission within not vary with the time of starting renal replacement therapy (prevalence of 1b infection 83 and 67% for the former group [20] [21] [22] . The similar prevalence of genotypes in the two groups in this study, together patients commencing dialysis before or after 1990 respectively, P=NS ). Only two (4%) subjects had with a low incidence rate of <0.6%/year among patients with renal failure, suggest that nosocomial mixed infections, by genotypes 1a plus 2a, and 1b plus 2b respectively. Both had received cadaveric renal transmission is not a major problem in this cohort.
That mixed infections were only noted in two patients allografts following a period of haemodialysis in China. The two renal allograft recipients with genotype 6a who had received haemodialysis and renal transplantation in China raises the suspicion of suboptimal precauinfection had received allografts from the same donor before screening tests for HCV were available. The tionary measures or the coexistence of other risk factors leading to superinfections. The detection of prevalence of chronic hepatitis was similar between patients infected by 1b and non-1b genotypes (51 and identical genotype 6a in two renal allograft recipients 64% respectively, P=NS ). Among the 28 patients with with the same cadaveric donor strongly suggests transliver biopsy, the histological scores also did not differ mission of HCV via the renal allograft. significantly between patients infected by 1b (22 Due to the predominance of genotype 1b, the genopatients) and non-1b (2 genotype 6a, 2 genotype 1a, 1 typic impact on clinical manifestations in patients with genotype 2b, and 1 with mixed infection by genotypes renal failure cannot be ascertained for some genotypes 1a and 2a) genotypes: 'total histological' and 'inflam-in the present study. Nevertheless, the prevalence of matory activity' scores 6.3±5.9 and 4.8±3.8 for 1b chronic hepatitis as well as the histological scores do genotype, 10.3±9.0 and 8.3±6.4 for non-1b genotypes not differ between patients infected by 1b and non-1b respectively (P=NS). Anti-HCV was detectable in 48 genotypes. In this context we have previously demon-(96%) of the 50 HCV RNA seropositive patients with strated marked variations in the level of HCV RNA renal failure, and in all controls. The two anti-HCV-among haemodialysis patients infected by genotype 1b, negative subjects were renal allograft recipients infected and that their response to interferon therapy depended by genotypes 1b and 1b plus 2b. more on virus load than the genotype per se [23] . Furthermore, although the prevalence of chronic hepatitis is similar between dialysis patients and renal
Discussion
allograft recipients, liver disease is more severe in the latter group as indicated by the higher histological scores. The host immune status thus assumes an Our results show that 1b is the most prevalent HCV important role in the pathogenesis of liver disease genotype in patients on renal replacement therapy and non-renal failure subjects with post-transfusional among patients infected by the same HCV genotypes.
Clinicopathologic features of hepatitis C virus infection in renal
We conclude that the distribution of HCV genotypes allograft recipients. Transplantation 1994; 58: 996-1000 among patients on renal replacement therapy is similar 10. Morales JM, Campistol JM, Bruguera M, Andres A, to non-renal failure subjects with post-transfusional 14. Luengrojanakul P, Vareesangthip K, Chainuvati T et al.
Hepatitis C virus infection in patients with chronic liver disease or chronic renal failure and blood donors in Thailand. J Med
